Biovica International AB (BIOVIC B) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -76.60%, its profits have risen by 28.5%

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

SEK 157 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.15

Return on Equity

-321.29%

Price to Book

6.13

Revenue and Profits:

Net Sales:

2 Million

(Quarterly Results - Apr 2025)

Net Profit:

-21 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-10.13%

6 Months

-20.87%

1 Year

-76.94%

2 Years

-76.59%

3 Years

-93.9%

4 Years

-98.14%

5 Years

-98.32%

Biovica International AB for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

42.09%

EBIT Growth (5y)

-186.00%

EBIT to Interest (avg)

-84.49

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.50

Sales to Capital Employed (avg)

0.10

Tax Ratio

1.91%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

6.61

EV to EBIT

-2.04

EV to EBITDA

-2.29

EV to Capital Employed

7.57

EV to Sales

17.48

PEG Ratio

Dividend Yield

ROCE (Latest)

-370.11%

ROE (Latest)

-321.29%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Apr'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Apr 2025 is 0.00% vs 0.00% in Jan 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Apr 2025 is 8.77% vs -7.55% in Jan 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Apr'25",
        "Jan'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.30",
          "val2": "2.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-18.30",
          "val2": "-20.00",
          "chgp": "8.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-20.80",
          "val2": "-22.80",
          "chgp": "8.77%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-8,779.60%",
          "val2": "-9,797.90%",
          "chgp": "101.83%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Apr'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Apr 2025 is 17.81% vs 114.71% in Apr 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Apr 2025 is 29.81% vs -12.94% in Apr 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Apr'25",
        "Apr'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "8.60",
          "val2": "7.30",
          "chgp": "17.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-81.90",
          "val2": "-121.70",
          "chgp": "32.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.30",
          "chgp": "-33.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-87.60",
          "val2": "-124.80",
          "chgp": "29.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-10,023.20%",
          "val2": "-17,294.00%",
          "chgp": "727.08%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Apr'25 - QoQ

Apr'25

Jan'25

Change(%)

Net Sales

2.30

Operating Profit (PBDIT) excl Other Income

-18.30

-20.00

8.50%

Interest

0.20

0.00

Exceptional Items

0.00

Consolidate Net Profit

-20.80

-22.80

8.77%

Operating Profit Margin (Excl OI)

-8,779.60%

-9,797.90%

101.83%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Apr 2025 is 0.00% vs 0.00% in Jan 2025

Consolidated Net Profit

QoQ Growth in quarter ended Apr 2025 is 8.77% vs -7.55% in Jan 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Apr'25

Apr'25

Apr'24

Change(%)

Net Sales

8.60

7.30

17.81%

Operating Profit (PBDIT) excl Other Income

-81.90

-121.70

32.70%

Interest

0.20

0.30

-33.33%

Exceptional Items

0.00

Consolidate Net Profit

-87.60

-124.80

29.81%

Operating Profit Margin (Excl OI)

-10,023.20%

-17,294.00%

727.08%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Apr 2025 is 17.81% vs 114.71% in Apr 2024

Consolidated Net Profit

YoY Growth in year ended Apr 2025 is 29.81% vs -12.94% in Apr 2024

All Annual Results

Company CV

About Biovica International AB

Biovica International AB

Pharmaceuticals & Biotechnology

Biovica International AB is a Sweden-based biotechnology company. It develops and commercializes blood-based biomarker assays for the monitoring of cancer therapies and for prediction of patient outcome. The Company has focus on breast cancer and its main product DiviTum is a blood-based test, which measures the activity of the enzyme thymidine kinase-1 (TK) in blood serum or cell cultures. The Company collaborates with numerous institutions, such as Karolinska Institutet in Sweden and Dana Farber Cancer Institute, Washington University, Baylor College of Medicine, City of Hope Research & Treatment Center in the Unites States, as well as The International Breast Cancer Study Group (IBCSG) based in Switzerland and Breast International Group in Belgium.

Company Coordinates

Company Details

Uppsala Science Park , UPPSALA None : 752 37

Tel: 46 18 444483046 18 4444835

http://biovica.com/

Registrar Details